[An experience of using divasa in the treatment of XXXX ].

@entity1 @entity66 @entity25 @entity16 @entity1504 @entity148 @entity4148 @entity74 @entity56 @entity2880
AIM: To evaluate the clinical efficacy and safety of divasa in the treatment of @entity1 with @entity1504 . MATERIAL AND METHODS: The main group included 40 @entity1 (mean age 56.2  5.7 years) with asthenic/autonomic and vestibular/ @entity74 developed during chronic @entity66 . The severity of symptoms was measured with the Visual Analogue scale (VAS). Neuropsychological and psychoemotional status was assessed with MMSE, MFI-20, HAM-A, a subjective sleep questionnaire, a scheme for detection of signs of @entity4148 . Quality of life questionnaire (SF-36) and CGI scale were used as well. The plasma levels of fibrinogen and the @entity2880 factor were determined in all @entity1 . The control group included 40 @entity1 with chronic @entity1504 matched for age, sex and severity of @entity16 to the main group. RESULTS: The scores of asthenic symptoms, @entity148 , @entity25 and @entity4148 were decreased significantly that led to the improvement of quality of life of @entity1 . A significant decrease and normalization of the plasma levels of fibrinogen and the @entity2880 factor were identified in the @entity1 of the main group. The drug was well-tolerated, side-effects ( @entity56 ) were noted only in 5%. CONCLUSION: The positive effect of divasa on @entity1 's condition was demonstrated. The drug may be recommended for the use in complex treatment of these @entity1 .
